Literature DB >> 26108645

Clinical Findings and Natural History in Ten Unrelated Families with Juvenile and Adult GM1 Gangliosidosis.

João Stein Kannebley1, Laura Silveira-Moriyama2,3,4, Laís Orrico Donnabella Bastos1, Carlos Eduardo Steiner5,6.   

Abstract

We describe 12 subjects of ten unrelated families from the region of Campinas and the southern state of Minas Gerais, Brazil, who presented with juvenile (n = 4) and adult (n = 8) GM1 gangliosidosis. Data includes clinical history, physical examination, and ancillary exam findings. Six subjects presented initially with skeletal deformities, while the remaining six had neurological manifestations at onset. Over time, all exhibited a combination of osteoarticular and neurologic degeneration with varying degrees of severity. Corneal clouding, angiokeratomas, and inguinal hernia were seen in one individual each. Other features commonly described in lysosomal storage disorders were not found in this series, such as coarse faces, gingival hypertrophy, visceromegaly, and cherry red spot. All subjects presented with short stature, dysostosis multiplex, dysarthria, and impairment of activities of daily living, 10/12 had extrapyramidal signs, 8/12 had pyramidal signs, 8/12 had oculomotor abnormalities, 4/12 had behavioral alterations, and 2/12 had ataxia. None had seizures or Parkinsonism. All female subjects developed severe hip dysplasia and underwent arthroplasty due to chronic pain. A vertebral bone bar and os odontoideum, not previously described in this condition, were found in one patient each. There was no clear genotype-phenotype correlation regarding enzyme residual activity and clinical findings, since all subjects were compound heterozygous, but the p.T500A was the most frequent allele in eight families and was associated to Morquio B phenotype. Two sets of siblings allowed intrafamilial comparison revealing consistent features among the families. Interfamilial correlation among unrelated families presenting the same mutations was less consistent.

Entities:  

Year:  2015        PMID: 26108645      PMCID: PMC4582032          DOI: 10.1007/8904_2015_451

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  15 in total

1.  High frequency of type 1 GM1 gangliosidosis in southern Brazil.

Authors:  M H Severini; C D Silva; A Sopelsa; J C Coelho; R Giugliani
Journal:  Clin Genet       Date:  1999-08       Impact factor: 4.438

Review 2.  Acquired spinal cord lesion associated with os odontoideum causing deterioration in dystonic cerebral palsy: case report and review of the literature.

Authors:  P Amess; W K Chong; F J Kirkham
Journal:  Dev Med Child Neurol       Date:  1998-03       Impact factor: 5.449

3.  Progressive mental regression in siblings with Morquio disease type B (mucopolysaccharidosis IV B).

Authors:  R Giugliani; M Jackson; S J Skinner; C M Vimal; A H Fensom; N Fahmy; A Sjövall; P F Benson
Journal:  Clin Genet       Date:  1987-11       Impact factor: 4.438

Review 4.  Dystonia and parkinsonism in GM1 type 3 gangliosidosis.

Authors:  Emmanuel Roze; Eduard Paschke; Nathalie Lopez; Thomas Eck; Kunihiro Yoshida; Annie Maurel-Ollivier; Diane Doummar; Catherine Caillaud; Damien Galanaud; Thierry Billette de Villemeur; Marie Vidailhet; Anne Roubergue
Journal:  Mov Disord       Date:  2005-10       Impact factor: 10.338

Review 5.  Surgical treatment of cervical myeloradiculopathy associated with movement disorders: indications, technique, and clinical outcome.

Authors:  Albert S Wong; Eric M Massicotte; Michael G Fehlings
Journal:  J Spinal Disord Tech       Date:  2005-02

Review 6.  Clinical features of adult GM1 gangliosidosis: report of three Indian patients and review of 40 cases.

Authors:  Uday Muthane; Yasha Chickabasaviah; Chris Kaneski; Susurla K Shankar; Gayathri Narayanappa; Rita Christopher; Srikanth Subbamma Govindappa
Journal:  Mov Disord       Date:  2004-11       Impact factor: 10.338

7.  Genotypic and phenotypic characterization of Brazilian patients with GM1 gangliosidosis.

Authors:  Fernanda Sperb; Filippo Vairo; Maira Burin; Fabiana Quoos Mayer; Ursula Matte; Roberto Giugliani
Journal:  Gene       Date:  2012-10-06       Impact factor: 3.688

Review 8.  GM1 gangliosidosis: review of clinical, molecular, and therapeutic aspects.

Authors:  Nicola Brunetti-Pierri; Fernando Scaglia
Journal:  Mol Genet Metab       Date:  2008-06-03       Impact factor: 4.797

9.  Expression and characterization of 14 GLB1 mutant alleles found in GM1-gangliosidosis and Morquio B patients.

Authors:  Raül Santamaria; Amparo Chabás; John W Callahan; Daniel Grinberg; Lluïsa Vilageliu
Journal:  J Lipid Res       Date:  2007-07-30       Impact factor: 5.922

10.  Novel mutations (Asn 484 Lys, Thr 500 Ala, Gly 438 Glu) in Morquio B disease.

Authors:  Richard D Bagshaw; Sunqu Zhang; Alina Hinek; Marie Anne Skomorowski; Donald Whelan; Joe T R Clarke; John W Callahan
Journal:  Biochim Biophys Acta       Date:  2002-12-12
View more
  14 in total

1.  Intermittent enzyme replacement therapy with recombinant human β-galactosidase prevents neuraminidase 1 deficiency

Authors:  Amanda R Luu; Cara Wong; Vishal Agrawal; Nathan Wise; Britta Handyside; Melanie J Lo; Glenn Pacheco; Jessica B Felix; Alexander Giaramita; Alessandra d'Azzo; Jon Vincelette; Sherry Bullens; Stuart Bunting; Terri M Christianson; Charles M Hague; Jonathan H LeBowitz; Gouri Yogalingam
Journal:  J Biol Chem       Date:  2020-07-28       Impact factor: 5.157

2.  Infantile gangliosidoses: Mapping a timeline of clinical changes.

Authors:  Jeanine R Jarnes Utz; Sarah Kim; Kelly King; Richard Ziegler; Lynn Schema; Evelyn S Redtree; Chester B Whitley
Journal:  Mol Genet Metab       Date:  2017-04-29       Impact factor: 4.797

Review 3.  Lysosomal Leukodystrophies Lysosomal Storage Diseases Associated With White Matter Abnormalities.

Authors:  Gustavo H B Maegawa
Journal:  J Child Neurol       Date:  2019-02-13       Impact factor: 1.987

4.  Rapid Identification of New Biomarkers for the Classification of GM1 Type 2 Gangliosidosis Using an Unbiased 1H NMR-Linked Metabolomics Strategy.

Authors:  Benita C Percival; Yvonne L Latour; Cynthia J Tifft; Martin Grootveld
Journal:  Cells       Date:  2021-03-05       Impact factor: 6.600

5.  Case reports of juvenile GM1 gangliosidosisis type II caused by mutation in GLB1 gene.

Authors:  Parvaneh Karimzadeh; Samaneh Naderi; Farzaneh Modarresi; Hassan Dastsooz; Hamid Nemati; Tayebeh Farokhashtiani; Bibi Shahin Shamsian; Soroor Inaloo; Mohammad Ali Faghihi
Journal:  BMC Med Genet       Date:  2017-07-17       Impact factor: 2.103

6.  Distinct progression patterns of brain disease in infantile and juvenile gangliosidoses: Volumetric quantitative MRI study.

Authors:  Igor Nestrasil; Alia Ahmed; Josephine M Utz; Kyle Rudser; Chester B Whitley; Jeanine R Jarnes-Utz
Journal:  Mol Genet Metab       Date:  2017-12-20       Impact factor: 4.797

7.  Genotype-phenotype correlation of gangliosidosis mutations using in silico tools and homology modeling.

Authors:  Li Ou; Sarah Kim; Chester B Whitley; Jeanine R Jarnes-Utz
Journal:  Mol Genet Metab Rep       Date:  2019-07-17

8.  Morquio-like dysostosis multiplex presenting with neuronopathic features is a distinct GLB1-related phenotype.

Authors:  Sylvia Stockler-Ipsiroglu; Nahid Yazdanpanah; Mojgan Yazdanpanah; Marioara Moisa Popurs; Nataliya Yuskiv; Mara Lúcia Schmitz Ferreira Santos; Chong Ae Kim; Carolina Fischinger Moura de Souza; Charles Marques Lourenço; Carlos Eduardo Steiner; Andressa Federhen; Luciana Giugliani; Débora Maria Bastos Pereira; Luz Elena Durán-Carabali; Roberto Giugliani
Journal:  JIMD Rep       Date:  2021-03-08

Review 9.  Tuning protein folding in lysosomal storage diseases: the chemistry behind pharmacological chaperones.

Authors:  David M Pereira; Patrícia Valentão; Paula B Andrade
Journal:  Chem Sci       Date:  2018-01-10       Impact factor: 9.825

10.  Novel variants underlying autosomal recessive intellectual disability in Pakistani consanguineous families.

Authors:  Muhammad Ilyas; Stephanie Efthymiou; Vincenzo Salpietro; Nuzhat Noureen; Faisal Zafar; Sobiah Rauf; Asif Mir; Henry Houlden
Journal:  BMC Med Genet       Date:  2020-03-24       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.